Memantina Aluzime

Memantine hydrochloride, the active ingredient in Memantina Aluzime, is an NMDA receptor antagonist presented as an oral tablet for oral use. It is used to treat Alzheimer’s disease in adult patients, helping to improve cognition and functional abilities.

GNH USA supplies Memantina Aluzime as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable logistics for global distribution. Our network ensures timely delivery and regulatory support across multiple regions.

Memantine is an NMDA receptor antagonist indicated for the treatment of Alzheimer’s disease, addressing cognitive decline and functional impairment.

- Alzheimer’s disease (mild to moderate): improves memory, attention, and daily living activities - Alzheimer’s disease (moderate to severe): slows progression of functional decline and behavioral symptoms - Alzheimer’s disease (behavioral disturbances): may reduce agitation and aggression

Memantine may cause a range of adverse reactions, which are categorized by frequency.

Common Side Effects: - Dizziness - Headache - Constipation - Nausea - Fatigue - Confusion

Serious or Rare Side Effects: - Severe skin reactions (e.g., Stevens‑Johnson syndrome) - Seizures - Hallucinations or psychosis - Cardiac arrhythmias - Hepatic dysfunction - Suicidal thoughts or behavior

When prescribing memantine, clinicians should consider several safety factors.

- Renal impairment: adjust dose or monitor renal function closely - History of seizures: monitor for increased seizure activity - Concurrent use of other NMDA antagonists: avoid additive neurotoxicity - Pregnancy: use only if potential benefit justifies potential risk to fetus - Elderly patients: start at low dose and titrate slowly - Store at ambient temperature: keep in original container, protect from moisture and direct sunlight

Memantine can interact with other medicines, requiring attention to avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid): - Amantadine: increased risk of neurotoxicity - Concurrent NMDA antagonists (e.g., ketamine): additive central nervous system effects - High‑dose anticholinergics: may diminish memantine’s therapeutic benefit

Moderate Interactions (Monitor Closely): - CNS depressants (benzodiazepines, opioids): enhanced sedation or dizziness - Loop diuretics (e.g., furosemide): possible increase in memantine plasma concentrations - Antihypertensive agents: monitor blood pressure for additive hypotensive effect